Patents by Inventor TODD ROSENGART

TODD ROSENGART has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220348921
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 3, 2022
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Patent number: 11421229
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 23, 2022
    Assignee: Baylor College of Medicine
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Publication number: 20220143142
    Abstract: Embodiments of the disclosure provide methods and compositions related to improving cardiomyocyte production by exposing starting cells to ETV2 and/or VEGF. The starting cells in specific embodiments are fibroblasts and/or endothelial cells, and following exposure to ETV2 and/or VEGF the resultant cells are exposed to one or more cardiomyocyte transdifferentiation factors, such as GATA4, myocyte enhancer factor-2c (Mef2c), T-box transcription factor 5 (TBX5), or a combination thereof. The produced cardiomyocytes are provided to individuals in need thereof, in particular embodiments.
    Type: Application
    Filed: March 17, 2020
    Publication date: May 12, 2022
    Inventors: Megumi Mathison, Todd Rosengart, Vivek P. Singh, Deepthi Sanagasetti, Jaya Pratap Pinnamaneni, Jianchang Yang
  • Publication number: 20180066252
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: February 19, 2016
    Publication date: March 8, 2018
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Patent number: 8694441
    Abstract: A method of predicting a quality of a professional based on quality measures of the professional is provided. The method includes collecting recommendations associated with the professional and determining an independent variable for the professional based on the recommendations received for the professional. Here, the independent variable reflects the quality of the professional. The method also includes comparing the independent variable with quality measures associated with the professional and generating a model based on the comparison between the independent variable and the quality measures. The model associates each of the quality measures with the quality of the professional. Particularly, the model assigns a weight to each of the quality measures based on the probativeness of the quality measure in relation to the quality of the professional. Thus, the quality measure of the professional may be used to determine the overall quality of the professional.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: April 8, 2014
    Assignee: MDX Medical, Inc.
    Inventors: Mitchel Rothschild, Christine Parlamis, Todd Rosengart
  • Publication number: 20020076395
    Abstract: The present invention provides adipose tissue modified with a vector comprising or encoding, in which case it expresses, an anti-angiogenic factor, an angiogenic substance, an apoptotic factor, an adipsin protein or an Ob protein. Also provided is adipose tissue modified with a vector comprising a promoter and, operably linked thereto, a DNA sequence encoding a secreted protein. Methods of therapeutically treating adipose tissue and expressing a secreted protein in adipose tissue are also provided. The adipose tissue is optionally in the form of an implant, which can further comprise a lymphogenic protein or a vector that comprises and expresses a lymphogenic gene.
    Type: Application
    Filed: December 23, 1998
    Publication date: June 20, 2002
    Inventors: RONALD G. CRYSTAL, CHRISTOPHER J. MAGOVERN, TODD ROSENGART, LLOYD HOFFMAN, MIA TALMOR